3-amino-1-methyl-5-morpholin-4-yl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one | 157224-54-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 3-amino-1-methyl-5-morpholin-4-yl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one
• 英文别名: 1,3-dihydro-1-methyl-3-amino-5-(N-morpholinyl)-2H-1,4-benzodiazepine-2-one；3-amino-1-methyl-5-morpholin-4-yl-3H-1,4-benzodiazepin-2-one
• CAS: 157224-54-9
• 化学式: C₁₄H₁₈N₄O₂
• 分子量: 274.323
• InChiKey: BVQHOZQTEPJWST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  71.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  异氰酸间甲苯酯 、 3-amino-1-methyl-5-morpholin-4-yl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one 以 四氢呋喃 为溶剂， 生成 N-(2,3-dihydro-1-methyl-2-oxo-5-(4-morpholino)-1H-1,4-benzodiazepin-3-yl)-N'-3-methylphenylurea
  参考文献：
  名称：

  Carbamate Oxime Reduction: A New Route to C3-Amino-1,4-benzodiazepines

  摘要：

  描述了一种温和的还原方法，将C3-氧肟基-1,4-苯二氮杂平还原为C3-氨基衍生物。关键步骤涉及形成一个碳酸酯氧肟中间体。与母体C3-氧肟相比，C3-(乙氨基羰基)氧肟基-1,4-苯二氮杂平对氢化具有更高的反应性，使得在常温下使用碳载钯进行还原成为可能。这种温和的条件更适合于像3,5-二氨基-1,4-苯二氮杂平这样的敏感胺。

  DOI：

  10.1055/s-1994-25513
• 作为产物：
  描述：

  [(1-methyl-5-morpholin-4-yl-2-oxo-1,4-benzodiazepin-3-ylidene)amino] N-ethylcarbamate 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 3-amino-1-methyl-5-morpholin-4-yl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one
  参考文献：
  名称：

  Carbamate Oxime Reduction: A New Route to C3-Amino-1,4-benzodiazepines

  摘要：

  描述了一种温和的还原方法，将C3-氧肟基-1,4-苯二氮杂平还原为C3-氨基衍生物。关键步骤涉及形成一个碳酸酯氧肟中间体。与母体C3-氧肟相比，C3-(乙氨基羰基)氧肟基-1,4-苯二氮杂平对氢化具有更高的反应性，使得在常温下使用碳载钯进行还原成为可能。这种温和的条件更适合于像3,5-二氨基-1,4-苯二氮杂平这样的敏感胺。

  DOI：

  10.1055/s-1994-25513

文献信息

• Succinoylaminobenzodiazepines as inhibitors of Abeta protein production
  申请人：Olson E. Richard

  公开号：US20060025407A1

  公开（公告）日：2006-02-02

  This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

  这项发明涉及具有以下结构式（I）的新型内酰胺，以及它们的药物组合物和使用方法。这些新型化合物抑制淀粉样前体蛋白的加工，更具体地说，抑制Aβ肽的产生，从而防止神经沉积物的淀粉样蛋白形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经疾病的治疗，如阿尔茨海默病和唐氏综合征。
• Benzodiazepine derivatives as app modulators
  申请人：——

  公开号：US20040082572A1

  公开（公告）日：2004-04-29

  A novel class of 1,4- and 1,5-benzodiazepines of formula (I) is disclosed. The compounds modulate the processing of amyloid precursor protein by &ggr;-secretase, and hence find use in the treatment or prevention of conditions associated with the deposition of &bgr;-amyloid, such as Alzheimer's disease. 1

  公开了一种式(I)的新型1,4-和1,5-苯二氮平类化合物。这些化合物调节&ggr;-分泌酶对淀粉样前体蛋白的加工作用，因此可用于治疗或预防与&bgr;-淀粉样蛋白沉积相关的疾病，如阿尔茨海默病。
• [EN] BENZODIAZEPINE DERIVATIVES AS APP MODULATORS<br/>[FR] DERIVES DE BENZODIAZEPINE UTILISES COMME MODULATEURS DE LA PROTEINE PRECURSEUR AMYLOIDE (APP)
  申请人：MERCK SHARP & DOHME

  公开号：WO2001090084A1

  公开（公告）日：2001-11-29

  A novel class of 1,4- and 1,5-benzodiazepines of formula (I) is disclosed. The compounds modulate the processing of amyloid precursor protein by η-secretase, and hence find use in the treatment or prevention of conditions associated with the deposition of β-amyloid, such as Alzheimer's disease.

  一种新型的1,4-和1,5-苯二氮平类化合物的式(I)被揭示。这些化合物通过调节η-分泌酶对淀粉样前体蛋白的加工，因此可用于治疗或预防与β-淀粉样蛋白沉积有关的疾病，如阿尔茨海默病。
• Succinoylamino benzodiazepines as inhibitors of Abeta protein production
  申请人：Olson E. Richard

  公开号：US20060122169A1

  公开（公告）日：2006-06-08

  This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有以下公式（I）的新型内酰胺，其制药组合物以及使用方法。这些新型化合物抑制淀粉样前体蛋白的加工，更具体地说，抑制Aβ肽的产生，从而防止神经沉积物的淀粉样蛋白形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经系统疾病的治疗，例如阿尔茨海默病和唐氏综合症。
• SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION
  申请人：Olson Richard E.

  公开号：US20080207602A1

  公开（公告）日：2008-08-28

  This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有公式（I）的新型内酰胺，它们的制药组合物及其使用方法。这些新化合物抑制淀粉样前体蛋白的加工，更具体地抑制Aβ-肽的产生，从而防止神经蛋白淀积的形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经系统疾病的治疗，例如阿尔茨海默病和唐氏综合症。